News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FPRT Bio Awarded The Michael J. Fox Foundation Therapeutic Development Initiative Grant for Study of XPro1595 in Parkinson's


12/13/2012 11:21:19 AM

NEW YORK, NY, December 10, 2012 /EIN Presswire/ -- FPRT Bio, a privately held clinical stage biopharmaceutical company, has been awarded a Therapeutic Development Initiative grant to study molecule, XPro(R)1595, in Parkinson's disease. The work will be conducted in collaboration with Emory University.

XPro1595 uses DN-TNF technology to neutralize soluble TNF to prevent chronic inflammation and nerve death, the hallmarks of neurodegenerative diseases such as Parkinson's disease. Because XPro1595 does not inhibit trans-membrane TNF or bind to TNF receptors, it has dramatically different biologic effects on the CNS compared to currently approved, non-selective TNF inhibitors. In addition to its anti-inflammatory effects, XPro1595 promotes nerve cell survival and remyelination, and increases CNS plasticity. This disease-modifying therapy has potential in the treatment of neurologic diseases where chronic neuroinflammation and nerve cell death are part of the core pathology, including ALS, MS, Alzheimer's and Parkinson's disease.

Malu Tansey PhD., associate professor of physiology at the Emory University School of Medicine, is a leader in the role of TNF and neuroinflammation in the pathogenesis of neurodegenerative and neuroinflammatory diseases. The TDI award is the latest in a series of grants to Dr. Tansey's laboratory supporting the development of XPro1595 as a treatment for Parkinson's disease. "The Michael J. Fox Foundation was one of the first to recognize the importance of chronic neuroinflammation in the pathophysiology of Parkinson's disease", says Dr. Tansey, "and their support has been essential in the development of this promising therapeutic strategy in this devastating disease."

FPRT Bio was formed to develop XPro1595 for the treatment of neurodegenerative diseases and explore its application in other indications. XPro1595 was discovered and developed at Xencor Inc. "The support of the Michael J. Fox Foundation highlights the potential of this novel therapeutic strategy in the treatment of Parkinson's disease" said RJ Tesi MD, CEO of FPRT Bio. "Because safety pharmacology and toxicology testing is complete, and a large scale GMP manufacturing process has been established, we can quickly transition into the clinic." FPRT Bio will be presenting XPro1595 at the Biotech Showcase 2013 in San Francisco on January 7th and 8th, 2013.

About The Michael J. Fox Foundation

As the world's largest private funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $304 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. Now through December 31, 2012, all new and increased giving to The Michael J. Fox Foundation, as well as gifts from donors who have not given since 2010 or earlier, will be matched on a dollar-for-dollar basis with the $50-million Brin Wojcicki Challenge, launched by Sergey Brin and Anne Wojcicki.

About Emory University School of Medicine

Emory University School of Medicine is ranked among the nation's finest institutions for education, biomedical research and patient care, with more than 3,200 regular and volunteer faculty and more than 530 students. The school trains over 1,100 residents and fellows in 88 accredited programs, and has five health professions programs. The school is known for its research and treatment in heart disease, cancer, neurosciences, transplantation, infectious disease, orthopaedics, renal disease, ophthalmology and geriatrics. Physician faculty in Emory's hospitals, affiliate teaching hospitals, and outpatient venues are responsible for 4 million patient service visits annually.

FPRT Bio Contact:

RJ Tesi, MD CEO and President

rtesi@fprtbio.com

+1.510.396.5709

3 W. Olive Street, Suite 205

Scranton, PA 18508


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES